A Patient’s Guide to Macular Degeneration: Symptoms and Treatment
Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...
Thought Leadership & Innovation Foundation (TLI) Initiatives Raise Awareness of Age-related Macular Degeneration (AMD) and Low Vision
Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those affected by AMD. Together, TLI and AMDF are dedicated to advancing awareness, ...
Serious eye disease Age-Related Macular Degeneration (AMD) recognized with official awareness month: Canadian Ophthalmological Society
The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...
Onlymyhealth1d
Ageing and Vision: Expert Explains How Our Eyes Change As We Age
Our vision declines as we age leading to the development of various eye conditions such as presbyopia cataracts and glaucoma ...
Managed Healthcare Executive2d
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...
Optician's warning to 'stop habit' or risk 'silent killer' that is on rise
With February marking Age-related Macular Degeneration (AMD) Awareness Month 2025 in the UK, recent NHS statistics have shown ...
East Texas eye doctor raises awareness of age-related macular degeneration
Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular degeneration.
Pharm Exec2d
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Business Wire2d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Pharmabiz1d
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
PharmiWeb2d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...